Collegium Pharmaceutical (NASDAQ:COLL) Hits New 1-Year Low - Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $28.30 and last traded at $28.30, with a volume of 534 shares. The stock had previously closed at $28.62.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on COLL shares. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $42.60.

Collegium Pharmaceutical Price Performance

The stock has a fifty day moving average of $30.61 and a two-hundred day moving average of $34.05. The stock has a market capitalization of $939.77 million, a price-to-earnings ratio of 12.56 and a beta of 0.82. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in COLL. GAMMA Investing LLC grew its position in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 792 shares during the period. CWM LLC raised its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after acquiring an additional 736 shares during the period. TD Private Client Wealth LLC lifted its position in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after acquiring an additional 483 shares in the last quarter. Virtus Fund Advisers LLC acquired a new position in Collegium Pharmaceutical in the 3rd quarter worth $72,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Collegium Pharmaceutical by 61.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock worth $239,000 after purchasing an additional 2,352 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.